Add this topic to your myFT Digest for news straight to your inbox
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
Booming sector raises tough questions for ESG investors
Breakthrough medicine will now be subject to further review by committee of independent experts
Drugmaker releases promising trial results for a pill and expects to enter China this year
Nice fails to approve Enhertu due to value-for-money concerns despite it being recommended in Scotland
US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
New Pasteur Institute head highlights risks posed by shortages of money, staff and political goodwill
GHO Capital has put contract research group FairJourney Biologics up for sale
Replacing a top researcher with a private sector manager would send entirely the wrong signal
US biotech group’s data suggests dominance of Novo Nordisk and Eli Lilly in the anti-obesity segment could be challenged in a few years
Leaving the EU was supposed to liberate Britain’s cumbersome approvals system and unlock new industries. What is going wrong?
German pharma group finds no unexpected side effects during trial, including at higher doses
Head of Cancer Research UK calls for more investment and points to heavy reliance on philanthropic funding
Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage
New molecule proves effective in animals against several drug-resistant bacteria
Large study further boosts fast-evolving efforts to predict and prevent neurogenerative diseases
Sovereign wealth funds Temasek and Mubadala in talks to fund biotech groups harnessing mind-altering substances
Pharma companies, while talking up pipelines, are turning to deals to boost their growth outlook
Chief executive says customers very willing to pay for Wegovy from their own pockets
Start-ups say new technology could help end animal testing by pharma companies
Investing in new oncology drugs without building up an effective arsenal against infections is a false economy
Danish drugmaker reports better than expected earnings for 2023
Mounjaro has achieved 22.5 per cent loss of body weight in trials
International Edition